0907 GMT - AstraZeneca is among the most mentioned companies across news items over the past three hours, according to Factiva data. The Anglo-Swedish pharma giant's shares rose after the company reported a significant rise in second-quarter revenue and earnings per share, ahead of market views, and backed its full-year guidance. Core earnings per share rose 25% on year to $2.15, comfortably beating a company-provided consensus of $1.98, while total revenue for the quarter increased to $11.42 billion from $10.77 billion, beating consensus of $10.97 billion, as each of its non-Covid-19 therapy areas saw double-digit growth. The company also backed its guidance for 2023 at constant-exchange rates, saying it expects total revenue to increase by a low-to-mid single-digit percentage. Excluding Covid-19 medicines, total revenue is expected to increase by a low double-digit percentage, and core EPS is expected to increase by a high single-digit to low double-digit percentage. "Overall, we view this as a robust set of results highlighting strong commercial execution across the first half," Shore Capital analyst Sean Conroy said in a research note. Shares at 0855 GMT were up 4.6% at 11,188.0 pence. Dow Jones & Co. owns Factiva. (joseph.hoppe@wsj.com)

(END) Dow Jones Newswires

July 28, 2023 05:22 ET (09:22 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2023 a Dic 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Dic 2022 a Dic 2023 Clicca qui per i Grafici di Astrazeneca